Mar 25 |
Lucid Diagnostics reports preliminary Q4 results
|
Mar 25 |
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
|
Mar 25 |
Earnings Scheduled For March 25, 2024
|
Mar 22 |
Earnings Preview: Lucid Diagnostics
|
Mar 21 |
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
|
Mar 20 |
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
|
Mar 12 |
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
|
Feb 8 |
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
|
Dec 12 |
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
|
Dec 11 |
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
|